Depression Therapeutics Market

Depression Therapeutics Market, By Drug Type [Antidepressants (Selective Serotonin Reuptake Inhibitors (SSRIs), Selective Norepinephrine Reuptake Inhibitors (SNRIs), Serotonin Modulators, Tricyclic & Tetracyclic Antidepressants, and Atypical Antidepressants), Antipsychotics, Others], By Indication (Major Depressive Disorder (MDD), Bipolar Disorder, Dysthymic Disorder, Postpartum Depression, Seasonal Affective Disorder (SAD), Premenstrual Dysphoric Disorder (PMDD), Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Depression therapeutics are medications that can help relieve the symptoms of depression and are also used in the treatment of some other conditions. Antidepressants can treat the symptoms of depression or other mental health problems. But they don’t always deal with the causes. Doctors will often prescribe them alongside talking therapy, to help deal with the causes of mental health problems. There are several different types of antidepressants. They mostly affect the same brain chemicals and cause similar effects. But some people may respond to certain antidepressants better than others.

The different types are:

• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)
• Tricyclics and tricyclic-related drugs
• Monoamine Oxidase Inhibitors (MAOIs)
• Others

Market Dynamics

The key players in the pharmaceutical industry are focusing on the development of drugs by conducting various clinical trials and research operations. Thus, increasing research and development activities by market players are expected to drive the growth of the global depression therapeutics market over the forecast period. For instance, in November 2022, Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, announced the initiation of dosing in the company’s Phase 1 clinical trial of ABX-002 in healthy volunteers. ABX-002 is a potent and selective brain-boosting thyroid receptor beta (TRβ) agonist that Autobahn is evaluating as a potential adjunctive treatment for people with major depressive disorder (MDD) who are experiencing an inadequate response to their antidepressant.

Key features of the study:

• This report provides an in-depth analysis of the global depression therapeutics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global depression therapeutics market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Johnson & Johnson, GlaxoSmithKline plc., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited., Eli Lilly and Company, Sanofi S.A., Pfizer, Inc., Allergan plc., H. Lundbeck A/S, Alkermes, Allergan, Novartis AG, Biogen, Sage Therapeutics, Inc., and AbbVie Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global depression therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global depression therapeutics market.

Detailed Segmentation:

• Global Depression Therapeutics Market, By Drug Type:
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Selective Norepinephrine Reuptake Inhibitors (SNRIs)
• Serotonin Modulators
• Tricyclic & Tetracyclic Antidepressants
• Atypical Antidepressants
• Antidepressants
• Antipsychotics
• Others
• Global Depression Therapeutics Market, By Indication:
• Major Depressive Disorder (MDD)
• Bipolar Disorder
• Dysthymic Disorder
• Postpartum Depression
• Seasonal Affective Disorder (SAD)
• Premenstrual Dysphoric Disorder (PMDD)
• Others
• Global Depression Therapeutics Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Depression Therapeutics Market, By Region:
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa
• Company Profiles
• Johnson & JohnsonGlaxoSmithKline plc.
• Otsuka Pharmaceutical Co., Ltd.
• Takeda Pharmaceutical Company Limited.
• Eli Lilly and Company
• Sanofi S.A.
• Pfizer, Inc.
• Allergan plc.
• H. Lundbeck A/S
• Alkermes
• Allergan
• Novartis AG
• Biogen
• Sage Therapeutics, Inc.
• AbbVie Inc.